Quick Answer
ROCKET PHARMACEUTICALS, INC. reported Cash and Equivalents of $77.56 million for fiscal year 2025.
ROCKET PHARMACEUTICALS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $77.56M | -52.6% |
| 2024 | $163.63M | +192.7% |
| 2023 | $55.90M | -60.2% |
| 2022 | $140.52M | -39.6% |
| 2021 | $232.69M | -21.7% |
| 2020 | $297.10M | +60.3% |
| 2019 | $185.38M | +66.5% |
| 2018 | $111.36M | +513.8% |
| 2017 | $18.14M | -39.1% |
| 2016 | $29.80M | -62.8% |
| 2015 | $80.04M | +2112.3% |
| 2014 | $3.62M | -71.7% |
| 2013 | $12.79M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $75.95M | +15.8% | +131.4% |
| June 30, 2025 | $32.82M | -15.0% | -34.1% |
| March 31, 2025 | $49.81M | +41.2% | -69.6% |
| December 31, 2024 | $163.63M | +192.7% | +149.4% |
| September 30, 2024 | $65.60M | -70.9% | +69.9% |
| June 30, 2024 | $38.61M | -14.4% | +9.4% |
| March 31, 2024 | $35.28M | -45.4% | -36.9% |
| December 31, 2023 | $55.90M | -60.2% | -75.2% |
- ROCKET PHARMACEUTICALS, INC. showed a decrease of -52.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2013–2025 period, ROCKET PHARMACEUTICALS, INC.’s cash and equivalents has grown by 506.3% (from $12.79 million to $77.56 million).
- The most recent figure is from ROCKET PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: